Skip to main content
Top
Published in: Breast Cancer Research 6/2003

Open Access 01-12-2003 | Research article

Health food store recommendations: implications for breast cancer patients

Authors: Edward Mills, Edzard Ernst, Rana Singh, Cory Ross, Kumanan Wilson

Published in: Breast Cancer Research | Issue 6/2003

Login to get access

Abstract

Background

Many breast cancer patients use complementary and alternative medicine (CAM). We aimed to determine what advice health food store employees present to individuals seeking treatment options for breast cancer.

Methods

Eight data gatherers asked employees of all retail health food stores in a major Canadian city, what they recommended for a patient with breast cancer. The data gatherers inquired about product safety, potential drug interactions, costs and efficacy. They also enquired about employee training related to the products.

Results

Thirty-four stores were examined. A total of 33 different products were recommended, none of which are supported by sufficient evidence of efficacy. The average cost of the products they recommended was $58.09 (CAD) (minimum $5.28, median $32.99, maximum $600) per month. Twenty-three employees (68%) did not ask whether the patient took prescription medications. Fifteen employees (44%) recommended visiting a healthcare professional (naturopaths (9), physicians (5), nutritionists (1). Three employees (8.8%) discussed potential adverse effects of the products. Eight employees (23.5%) discussed the potential for drug interactions. Two employees (5.9%) suggested a possible cure with the products and one employee (2.9%) suggested discontinuing Tamoxifen. Four employees (11.8%) recommended lifestyle changes and three employees (8.8%) recommended books for further reading on the products.

Conclusion

This study draws attention to the heterogeneity of advice provided by natural health food stores to individuals seeking treatments for breast cancer, and the safety and cost implications of some of the products recommended. Physicians should enquire carefully about the use of natural health food products by patients with breast cancer. Regulators need to consider regulations to protect vulnerable patients from incurring significant costs in their purchasing of natural health food products lacking evidence of benefit and of questionable safety.
Literature
1.
go back to reference Berger E: Berger Population Health Monitor. Toronto: Hay Associates. 2002 Berger E: Berger Population Health Monitor. Toronto: Hay Associates. 2002
2.
go back to reference Alferi SM, Antoni MH, Ironson G, Kilbourn KM, Carver CS: Factors predicting the use of complementary therapies in a multi-ethnic sample of early-stage breast cancer patients. J Am Med Womens Assoc. 2001, 56: 120-123. Alferi SM, Antoni MH, Ironson G, Kilbourn KM, Carver CS: Factors predicting the use of complementary therapies in a multi-ethnic sample of early-stage breast cancer patients. J Am Med Womens Assoc. 2001, 56: 120-123.
3.
go back to reference Jonas WB: Alternative medicine – learning from the past, examining the present, advancing to the future. JAMA. 1998, 280: 1616-1618. 10.1001/jama.280.18.1616.CrossRefPubMed Jonas WB: Alternative medicine – learning from the past, examining the present, advancing to the future. JAMA. 1998, 280: 1616-1618. 10.1001/jama.280.18.1616.CrossRefPubMed
4.
go back to reference US Food and Drug Administration: Risk of drug interactions with St. John's Wort. JAMA. 2000, 283: 1679-CrossRef US Food and Drug Administration: Risk of drug interactions with St. John's Wort. JAMA. 2000, 283: 1679-CrossRef
5.
go back to reference Cassileth BR: Evaluating complementary and alternative therapies for cancer patients. CA Cancer J Clin. 1999, 49: 362-375.CrossRefPubMed Cassileth BR: Evaluating complementary and alternative therapies for cancer patients. CA Cancer J Clin. 1999, 49: 362-375.CrossRefPubMed
6.
go back to reference Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998, 83: 777-782. 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O.CrossRefPubMed Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998, 83: 777-782. 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O.CrossRefPubMed
7.
go back to reference Morris KT, Johnson N, Homer L, Walts D: A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg. 2000, 179: 407-411. 10.1016/S0002-9610(00)00358-5.CrossRefPubMed Morris KT, Johnson N, Homer L, Walts D: A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg. 2000, 179: 407-411. 10.1016/S0002-9610(00)00358-5.CrossRefPubMed
8.
go back to reference Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A: Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002, 94: 1247-1249. 10.1093/jnci/94.16.1247.CrossRefPubMed Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A: Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002, 94: 1247-1249. 10.1093/jnci/94.16.1247.CrossRefPubMed
9.
go back to reference Spaulding-Albright N: A review of some herbal and related products commonly used in cancer patients. J Am Diet Assoc. 1997, 97: S208-S215. 10.1016/S0002-8223(97)00767-0.CrossRefPubMed Spaulding-Albright N: A review of some herbal and related products commonly used in cancer patients. J Am Diet Assoc. 1997, 97: S208-S215. 10.1016/S0002-8223(97)00767-0.CrossRefPubMed
10.
go back to reference Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001, 61: 2163-2175.CrossRefPubMed Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001, 61: 2163-2175.CrossRefPubMed
11.
go back to reference Adler SR, Fosket JR: Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract. 1999, 48: 453-458.PubMed Adler SR, Fosket JR: Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract. 1999, 48: 453-458.PubMed
12.
go back to reference Gotay CC, Dumitriu D: Health food store recommendations for breast cancer patients. Arch Fam Med. 2000, 9: 692-699. 10.1001/archfami.9.8.692.CrossRefPubMed Gotay CC, Dumitriu D: Health food store recommendations for breast cancer patients. Arch Fam Med. 2000, 9: 692-699. 10.1001/archfami.9.8.692.CrossRefPubMed
13.
go back to reference Stoffer S, Szpunar W, Coleman B, Mallos P: Advice from some health food stores. JAMA. 1980, 244: 2044-2046. Stoffer S, Szpunar W, Coleman B, Mallos P: Advice from some health food stores. JAMA. 1980, 244: 2044-2046.
14.
go back to reference Aigner C: Advice in healthfood stores. Nutr Forum. 1998, 5: 1-4. Aigner C: Advice in healthfood stores. Nutr Forum. 1998, 5: 1-4.
15.
go back to reference Haidet JM: Poor advice plus doubletalk: a probe of 'health food' stores in Central Ohio. Nutr Forum. 1992, 9: 6-9. Haidet JM: Poor advice plus doubletalk: a probe of 'health food' stores in Central Ohio. Nutr Forum. 1992, 9: 6-9.
16.
go back to reference US Food and Drug Administration: Unsubstantiated Claims and Documented Health Hazards in the Dietary Supplement Marketplace. Rockville, Maryland: Food and Drug Administration. 1993 US Food and Drug Administration: Unsubstantiated Claims and Documented Health Hazards in the Dietary Supplement Marketplace. Rockville, Maryland: Food and Drug Administration. 1993
17.
go back to reference Mills EJ, Singh R, Bast L, Kiani P, Hart J, Majlesi A, Kawasaki M, Wilson K: Emerging issues associated with HIV patients seeking advice from Health Food Stores. In International Scientific Conference on Complementary, Alternative & Integrative Medicine Research: April 13, 2002; Harvard Medical School, Boston. Can J Pub Health. 2003, Mills EJ, Singh R, Bast L, Kiani P, Hart J, Majlesi A, Kawasaki M, Wilson K: Emerging issues associated with HIV patients seeking advice from Health Food Stores. In International Scientific Conference on Complementary, Alternative & Integrative Medicine Research: April 13, 2002; Harvard Medical School, Boston. Can J Pub Health. 2003,
18.
go back to reference Mills EJ, Singh R, Ross CP, Ernst E, Ray JG: Impact of Federal Safety Advisories of health food store advice. CMAJ. 2003, Mills EJ, Singh R, Ross CP, Ernst E, Ray JG: Impact of Federal Safety Advisories of health food store advice. CMAJ. 2003,
19.
go back to reference Phillips LG, Nichols MH, King WD: Herbs and HIV: the health food industry's answer. South Med J. 1995, 88: 911-913.CrossRefPubMed Phillips LG, Nichols MH, King WD: Herbs and HIV: the health food industry's answer. South Med J. 1995, 88: 911-913.CrossRefPubMed
20.
go back to reference Ernst E, Schmidt K: Health risks over the Internet: advice offered by 'medical herbalists' to a pregnant woman. Wien Med Wochenschr. 2002, 152: 190-192. 10.1046/j.1563-258X.2002.01113.x.CrossRefPubMed Ernst E, Schmidt K: Health risks over the Internet: advice offered by 'medical herbalists' to a pregnant woman. Wien Med Wochenschr. 2002, 152: 190-192. 10.1046/j.1563-258X.2002.01113.x.CrossRefPubMed
21.
go back to reference Geyer C, Hammond L, Johnson T, Smetzer L, Coyle J, Drengler R, Von Hoff D, De Jager R, Rowinsky E: Dose-schedule optimization the hexacyclic camptothecin (CPT) analog dx-8951f: a phase I and pharmacokinetic study with escalation of both treatment duration and dose [meeting abstract]. Proc Ann Meet Am Soc Clin Oncol. 1999, A813- Geyer C, Hammond L, Johnson T, Smetzer L, Coyle J, Drengler R, Von Hoff D, De Jager R, Rowinsky E: Dose-schedule optimization the hexacyclic camptothecin (CPT) analog dx-8951f: a phase I and pharmacokinetic study with escalation of both treatment duration and dose [meeting abstract]. Proc Ann Meet Am Soc Clin Oncol. 1999, A813-
22.
go back to reference Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun. 1994, 199: 1504-1508. 10.1006/bbrc.1994.1401.CrossRefPubMed Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun. 1994, 199: 1504-1508. 10.1006/bbrc.1994.1401.CrossRefPubMed
23.
go back to reference Lockwood K, Moesgaard S, Yamamoto T, Folkers K: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun. 1995, 212: 172-177. 10.1006/bbrc.1995.1952.CrossRefPubMed Lockwood K, Moesgaard S, Yamamoto T, Folkers K: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun. 1995, 212: 172-177. 10.1006/bbrc.1995.1952.CrossRefPubMed
24.
go back to reference Babu JR, Sundravel S, Arumugam G, Renuka R, Deepa N, Sachdanandam P: Salubrious effect of vitamin C and vitaminE on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels. Cancer Lett. 2000, 151: 1-5. 10.1016/S0304-3835(99)00340-7.CrossRefPubMed Babu JR, Sundravel S, Arumugam G, Renuka R, Deepa N, Sachdanandam P: Salubrious effect of vitamin C and vitaminE on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels. Cancer Lett. 2000, 151: 1-5. 10.1016/S0304-3835(99)00340-7.CrossRefPubMed
25.
go back to reference Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ. 1998, 158: 897-902.PubMedPubMedCentral Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ. 1998, 158: 897-902.PubMedPubMedCentral
26.
go back to reference Jain M, Miller AB: Tumor characteristics and survival of breast cancer patients in relation to premorbid diet and body size. Breast Cancer Res Treat. 1997, 42: 43-55. 10.1023/A:1005798124538.CrossRefPubMed Jain M, Miller AB: Tumor characteristics and survival of breast cancer patients in relation to premorbid diet and body size. Breast Cancer Res Treat. 1997, 42: 43-55. 10.1023/A:1005798124538.CrossRefPubMed
27.
go back to reference Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998, 16: 3649-3655.CrossRefPubMed Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998, 16: 3649-3655.CrossRefPubMed
28.
go back to reference Passalacqua R, Campione F, Caminiti C, Salvagni S, Barilli A, Bella M, Barni S, Barsanti G, Caffo O, Carlini P, Cinquemani G, Di Costanzo F, Giustini L, Labianca R, Mazzei A, Olmeo N, Paccagnella A, Toscano L, Cocconi G: Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. Lancet. 1999, 353: 1310-1314. 10.1016/S0140-6736(98)10253-2.CrossRefPubMed Passalacqua R, Campione F, Caminiti C, Salvagni S, Barilli A, Bella M, Barni S, Barsanti G, Caffo O, Carlini P, Cinquemani G, Di Costanzo F, Giustini L, Labianca R, Mazzei A, Olmeo N, Paccagnella A, Toscano L, Cocconi G: Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. Lancet. 1999, 353: 1310-1314. 10.1016/S0140-6736(98)10253-2.CrossRefPubMed
29.
go back to reference Montbriand MJ: Abandoning biomedicine for alternate therapies: oncology patients' stories. Cancer Nurs. 1998, 21: 36-45. 10.1097/00002820-199802000-00005.CrossRefPubMed Montbriand MJ: Abandoning biomedicine for alternate therapies: oncology patients' stories. Cancer Nurs. 1998, 21: 36-45. 10.1097/00002820-199802000-00005.CrossRefPubMed
30.
go back to reference US Food and Drug Administration: Letter to Health Care Professionals FDA Issues Consumer Advisory That Kava Products May be Associated with Severe Liver Injury. Rockville, Maryland: US Food and Drug Administration, Centre for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. 2002 US Food and Drug Administration: Letter to Health Care Professionals FDA Issues Consumer Advisory That Kava Products May be Associated with Severe Liver Injury. Rockville, Maryland: US Food and Drug Administration, Centre for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. 2002
31.
go back to reference Ernst E, Cohen MH: Informed consent in complementary and alternative medicine. Arch Intern Med. 2001, 161: 2288-2292. 10.1001/archinte.161.19.2288.CrossRefPubMed Ernst E, Cohen MH: Informed consent in complementary and alternative medicine. Arch Intern Med. 2001, 161: 2288-2292. 10.1001/archinte.161.19.2288.CrossRefPubMed
Metadata
Title
Health food store recommendations: implications for breast cancer patients
Authors
Edward Mills
Edzard Ernst
Rana Singh
Cory Ross
Kumanan Wilson
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr636

Other articles of this Issue 6/2003

Breast Cancer Research 6/2003 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine